Tocotrienol

Phase 2Small molecule

FFondazione IRCCS Istituto Nazionale dei Tumori, Milano

Tocotrienol is one of 22 small molecule programs targeting End Stage Liver Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

End Stage Liver DiseaseActive, not recruiting

Breast CancerActive, not recruiting

End Stage Liver DiseasePhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

22 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 3

Adenocard

Astellas

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Lexiscan

Astellas

Preclinical

1 6

Tocotrienol

FFondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Active, not recruiting

End Stage Liver Disease

NCT02581085

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Preoperative Use of Tocotrienol From Annatto Bixa Orellana L. in Breast Cancer Patients: a Prospective Clinical Trial.

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT04496492·50 enrolled

End Stage Liver Disease1 trial

Tocotrienol Against the Progression of End Stage Liver Disease

Active, not recruiting·CChandan Sen·Phase 2·NCT02581085·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Tocotrienol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tocotrienol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tocotrienol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fondazione IRCCS Istituto Nazionale dei Tumori, Milano company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFondazione IRCCS Istituto Nazionale dei Tumori, Milano

Tocotrienol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Breast Cancer1 trial

End Stage Liver Disease1 trial

References

Drug Info

Quick Facts

Related News